Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Retained Earnings (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Retained Earnings for 10 consecutive years, with -$4.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 453100.0% to -$4.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.5 billion, a 453100.0% decrease, with the full-year FY2025 number at -$4.5 billion, down 453100.0% from a year prior.
  • Retained Earnings was -$4.5 billion for Q4 2025 at Ultragenyx Pharmaceutical, down from -$4.4 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$268000.0 in Q2 2025 to a low of -$4.5 billion in Q4 2025.
  • A 5-year average of -$1.8 billion and a median of -$1.9 billion in 2021 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 99.99% in 2025; the steepest drop was 453100.0% in 2025.
  • Ultragenyx Pharmaceutical's Retained Earnings stood at -$2.1 billion in 2021, then tumbled by 34.12% to -$2.8 billion in 2022, then fell by 21.81% to -$3.4 billion in 2023, then surged by 99.97% to -$1.0 million in 2024, then tumbled by 453100.0% to -$4.5 billion in 2025.
  • Per Business Quant, the three most recent readings for RARE's Retained Earnings are -$4.5 billion (Q4 2025), -$4.4 billion (Q3 2025), and -$268000.0 (Q2 2025).